Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea
Title:
Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea
Author:
Lee, Eui-Kyung Revil, Cedric Ngoh, Charles A. Lister, Johanna Kwon, Jeong-Mi Park, Mee-Hye Park, Seok-Jin Park, Young-Suk Shin, Sang-Joon Lee, Myung-Ah Lee, Nam-Su Zang, Dae-Young Bae, Eun-Jin Kang, Mi-Jeong